On December 11, 2025, Sunshine Biopharma Inc. held its annual meeting where directors were elected, the appointment of M&K CPAS as accountants for 2025 was ratified, and the 2023 Equity Incentive Plan was amended to authorize 683,000 shares. The election results showed strong support for the board members.